Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study.

[1]  M. Sporn,et al.  Carcinogenesis and cancer: different perspectives on the same disease. , 1991, Cancer research.

[2]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[3]  S. Lippman,et al.  Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. , 1989, International journal of radiation oncology, biology, physics.

[4]  Pierre Chambon,et al.  A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.

[5]  V. Giguère,et al.  Identification of a receptor for the morphogen retinoic acid , 1987, Nature.

[6]  S. Lippman,et al.  Retinoids as preventive and therapeutic anticancer agents (Part I). , 1987, Cancer treatment reports.

[7]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[8]  S. Shapshay,et al.  Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy , 1985, Cancer.

[9]  M. Sporn,et al.  Role of retinoids in differentiation and carcinogenesis. , 1983, Cancer research.

[10]  R. Mehta,et al.  Nuclear interactions of retinoic acid-binding protein in chemically induced mammary adenocarcinoma. , 1982, The Biochemical journal.

[11]  G. Mathé,et al.  DEGREE OF BRONCHIAL METAPLASIA IN HEAVY SMOKERS AND ITS REGRESSION AFTER TREATMENT WITH A RETINOID , 1982, The Lancet.

[12]  A. Matter,et al.  FROM VITAMIN A TO RETINOIDS IN EXPERIMENTAL AND CLINICAL ONCOLOGY: ACHIEVEMENTS, FAILURES, AND OUTLOOK , 1981, Annals of the New York Academy of Sciences.

[13]  G. Shklar,et al.  Retinoid inhibition of lingual carcinogenesis. , 1980, Oral surgery, oral medicine, and oral pathology.

[14]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[15]  W. Bollag.  Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinomas of mice. , 1974, European journal of cancer.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  A. Laplanche,et al.  [Retinoids and carotenoids in cancer chemoprevention trials]. , 1992, Bulletin du cancer.

[18]  C. Scully,et al.  Vitamin A related compounds in the chemoprevention of potentially malignant oral lesions and carcinoma. , 1992, European journal of cancer. Part B, Oral oncology.

[19]  U. Pastorino,et al.  Chemoprevention in the management of oral cancer: EUROSCAN and other studies. , 1992, European journal of cancer. Part B, Oral oncology.

[20]  C. Apfel,et al.  Synthetic Retinoids: Differential Binding to Retinoic Acid Receptors1 , 1991 .

[21]  O. Alfthan,et al.  Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. , 1983, European urology.

[22]  K. Rothman.  Estimation of confidence limits for the cumulative probability of survival in life table analysis. , 1978, Journal of chronic diseases.